glp 1 receptor brain Frontiers A sympathetic brake on gut

Description

The co-primary outcomes were changes in body weight and the Knee Injury and Osteoarthritis Outcome Score pain subscale from week 0 to 52 [47, 48]

Scenario 1: Compounded Semaglutide (No Insurance) First Month: Membership: Varies by promotional offer Compounded semaglutide: $151 (3-month pricing) Total Month 1: Approximately $190-$240 (depending on current membership offer) Months 2-3: Membership: Standard rate (verify on official site) Medication: $151/month (already paid for 3 months in Month 1) Total: Membership fee only Month 4 Onwards: Membership: Standard rate Medication: $151 (if re-ordering 3-month supply) Total: Membership + $151 every third month Annual Cost Estimate: Approximately $2,300-$2,800 (depending on membership rate) Scenario 2: Compounded Tirzepatide (No Insurance) First Month: Membership: Varies by promotional offer Compounded tirzepatide: $216 (3-month pricing) Total Month 1: Approximately $255-$305 (depending on current membership offer) Months 2-3: Membership: Standard rate Medication: $216/month (already paid for 3 months in Month 1) Total: Membership fee only Month 4 Onwards: Membership: Standard rate Medication: $216 (if re-ordering 3-month supply) Total: Membership + $216 every third month Annual Cost Estimate: Approximately $2,900-$3,500 (depending on membership rate) Scenario 3: FDA-Approved Wegovy (Insurance Approves) First Month: Membership: Varies by promotional offer Wegovy: Varies by plan (company states co-pays can be as low as $25/month-verify your specific co-pay with insurance) Total Month 1: Varies based on membership offer + co-pay Months 2 Onwards: Membership: Standard rate Wegovy: Co-pay (varies by plan) Total: Membership + co-pay monthly Annual Cost Estimate: Approximately $800-$1,200 (depending on membership rate and co-pay) Important: This assumes insurance approves and maintains coverage

GLP-1 RAs, in contrast, exert their effects systemically by reducing central adiposity, improving insulin sensitivity, and modulating autonomic tone and inflammation, key pathophysiologic drivers of OSA [1, 2]